2026. First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience. Mediterranean Journal of Hematology and Infectious Diseases. 18, 1 (Sep. 2026), e2026066. DOI:https://doi.org/10.4084/MJHID.2026.066.